Salivary Gland Cancer
Conditions
Keywords
Androgen receptor (AR)-positive, Salivary gland carcinoma, Darolutamide, luteinizing hormone-releasing hormone (LH-RH) analogue
Brief summary
This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma. Moreover, this study will evaluate the safety and efficacy of Darolutamide and Goserelin combination in patients with androgen receptor-positive salivary gland carcinoma.
Interventions
DRUGDarolutamide
Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
DRUGGoserelin
Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
Sponsors
National Cancer Center Hospital East
Bayer Yakuhin, Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Darolutamide monotherapy group: 1. Signed, written informed consent. 2. Patients older than 20 years. 3. Histologically confirmed any salivary duct carcinoma (SDC), adenocarcinoma (AC)(NOS), or Carcinoma ex pleomorphic adenoma. 4. Patients with locally recurrent(unresectable) or metastatic salivary gland carcinoma who are not applied for surgery or radiation treatment. 5. Presence of measurable or evaluable disease according to RECIST v1.1 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 7. Adequate organ or bone marrow function 8. Patients who agree to practice effective barrier contraception and refrain from sperm donation during the entire study treatment period and 3 months after the last dose of the study drug. Darolutamide and Goserelin combination therapy group: 1. Signed, written informed consent. 2. Patients older than 20 years. 3. Histologically confirmed as androgen receptor-positive salivary gland carcinoma at the medical institution. 4. Histologically confirmed as salivary gland carcinoma at the medical institution. 5. Patients with locally recurrent(unresectable) or metastatic salivary gland carcinoma who are not applied for surgery or radiation treatment. 6. Presence of measurable or evaluable disease according to RECIST v1.1 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 8. Adequate organ or bone marrow function 9. Patients who agree to practice effective barrier contraception refrain from sperm donation and stop breastfeeding during the entire study treatment period and through 3 months after the last dose of the study drug.
Exclusion criteria
Darolutamide monotherapy group: 1. Histologically confirmed as androgen receptor-negative salivary gland carcinoma at a central laboratory. 2. Prior treatment with AR inhibitors, CYP17 enzyme inhibitors, or LH-RH analogue. 3. Metastases in the brain/central nervous system (CNS). 4. Patients who are pregnant or breastfeeding. 5. Synchronous or metachronous malignancies. 6. Participant has a known history of HIV infection. 7. A positive test result for any of the followings: * HBsAg positive * HBsAb positive and hepatitis B virus (HBV)-DNA positive * HBcAb positive and HBV-DNA positive 8. Severe or uncontrolled concurrent heart disease or hypertension. 9. Inability to swallow oral medications. Darolutamide and Goserelin combination therapy group: 1. Prior treatment with AR inhibitors, CYP17 enzyme inhibitors, LH-RH analogue, Sex Hormones, or Gonadotropin 2. Prior treatment with Darolutamide or Goserelin. 3. Metastases in the brain/CNS. 4. Patients who are pregnant or breastfeeding. 5. Synchronous or metachronous malignancies. 6. Participant has a known history of HIV infection. 7. A positive test result for any of the followings: * HBsAg positive * HBsAb positive and HBV-DNA positive * HBcAb positive and HBV-DNA positive 8. Severe or uncontrolled concurrent heart disease or hypertension. 9. Inability to administer Darolutamide or Goserelin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Darolutamide monotherapy group: Objective response rate(ORR) assessed by investigators | Up to 13 month | The proportion of patients with confirmed tumor response of complete response (CR) or partial response (PR) per RECIST 1.1, as assessed by investigators |
| Darolutamide and Goserelin combination therapy group: Objective response rate(ORR) assessed by an Independent Review Committee | Up to 13 month | The proportion of patients with confirmed tumor response of CR or PR per RECIST 1.1, as assessed by an independent review committee |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DOR) | Up to 13 month | DOR will be defined among responders from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease as defined in RECIST version 1.1 or death, whichever occurred first. |
| Best Overall Response (BOR) | Up to 13 month | BOR will be defined as the best response recorded from the start of protocol treatment based on RECIST version 1.1 |
| Disease Control Rate (DCR) | Up to 13 month | DCR will be defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or SD for at least 6 weeks based on RECIST version 1.1. |
| Clinical Benefit Rate (CBR) | Up to 13 month | CBR will be defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or stable disease (SD) for at least 24 weeks based on RECIST version 1.1. |
| Clinical Benefit Duration (CBD) | Up to 13 month | CBD will be defined the period starting from the date of enrollment (start of treatment) and ending on the earlier of the date of determination of progression, the date of death from any cause, or the end of the study period. |
| Progression-Free Survival (PFS) | Up to 13 month | PFS will be defined as the time from the date of the initial dose of study intervention to the date of first documented disease progression as defined in the RECIST version 1.1, or death due to any cause, whichever occurred first. |
| Overall Survival (OS) | Up to 13 month | OS will be defined as the time from the date of the initial dose of study intervention to the date of the participant's death |
| Adverse events | Up to 30 days after the last dose | All adverse events, adverse events with undeniable causal relationship to the investigational drug, severe adverse events (SAEs) and SAEs with undeniable causal relationship to the investigational drug will be evaluated based on CTCAE version 5.0 |
| Quality of Life assessed using the EuroQol-5Dimention-5Level (EQ-5D-5L) questionnaire | Up to 30 days after the last dose | Changes from baseline to each time point in health-related quality of life will be measured using the European Quality of Life Five Dimension Five Level Scale Assessment Questionnaire (EQ-5D-5L). The EQ-5D-5L consists of a description and a health assessment. The health description consists of five dimensions (mobility, self-care, normal activities, pain / discomfort, and anxiety / depression), with each dimension identifying five levels of severity \[best (1) - worst (5)\]. Health assessment is assessed using a visual analogue scale (VAS)(\[worse (0) - better (100)\]. |
| Darolutamide monotherapy group: ORR assessed by an Independent Review Committee | Up to 13 month | The proportion of patients with confirmed tumor response of CR or PR per RECIST 1.1, as assessed by an independent review committee |
| Darolutamide and Goserelin combination therapy group: ORR assessed by investigators | Up to 13 month | The proportion of patients with confirmed tumor response of complete response (CR) or partial response (PR) per RECIST 1.1, as assessed by investigators |
| Comparison of androgen receptor (AR) test results in Darolutamide and Goserelin combination therapy group | Baseline | Comparison of AR test results between each institutional and a central assessment |
| Positivity of Ki-67 in Darolutamide and Goserelin combination therapy group | Baseline | The proportion of patients who have high expression of Ki-67 by a central assessment |
Countries
Japan
Contacts
STUDY_DIRECTORMakoto Tahara, MD, PhD
National Cancer Center Hospital East
STUDY_CHAIRNaomi Kiyota, MD, PhD
Kobe University Hospital
STUDY_CHAIRSusumu Okano, MD, PhD
National Cancer Center Hospital East
Outcome results
None listed